Looking for Support? Try MyHopeSpace

MyHopeSpace.com offers cancer patients, survivors, caregivers and their support network an easy way to communicate and share their stories, their struggles, and their accomplishments with other members. MyHopeSpace.com is owned and operated by Foundations of Hope, Inc., a Nebraska not-for-profit corporation.



Every journey through cancer is different, everyone gets involved for different reasons and people cope in many different ways whether they be the patient, friend, family or caregiver. MyHopeSpace.com is a site that can be a way to enhance their experience no matter what role they play. It also provides a place for hope.



It is normal to have feelings of sadness and anxiety after receiving a cancer diagnosis. It is also normal to feel lost and alone. Finding someone to talk to that knows what you are going through can provide hope for cancer patients and their friends and family members.

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap